Opsona draws new VC investment
Dublin – Trinity College Dublin spin-out Opsona Therapeutics, a specialist in autoimmune and inflammatory diseases, has announced that the Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3m to the second round financing announced in February. This brings the total value of the round to EUR21.3m. The new investors join Novartis Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba-Kernel in completing the round, which will enable Opsona to further expand its clinical development pipeline.
The proceeds will support the advancement of clinical trials targeting inflammatory diseases such as rheumatoid arthritis, lupus erythrematosus and solid organ transplant rejection. They will also be used to improve Opsona’s ability to clinically evaluate novel compounds for in-licensing aimed at treating autoimmune and inflammatory diseases. The money will fund the company over the next three years.